Additionally, CXCR2 antagonists such as SB225002 and SCH-527123 have shown promising preclinical anticancer activity, inhibiting tumor cell proliferation, migration, and therapy resistance across multiple cancer types [47–50]. Here, CXCR2 is linked to neoplasm.